home / stock / capr / capr articles

CAPR Articles, Capricor Therapeutics Inc.

Stock Information
Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com
Menu
CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...
What's Going On With Capricor Therapeutics Stock Friday? | Benzinga

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the t...
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy | Benzinga

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exo...

Pfizer Phase III DMD Gene Therapy Study Misses Goal | Benzinga

Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...

Capricor Advances in DMD Therapy With Positive Study Data | Benzinga

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year re...
What's Going On With Capricor Therapeutics Stock Tuesday? | Benzinga

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-la...

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting | Benzinga

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in...

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences | Benzinga

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos...
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13 | Benzinga

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos...

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy | Benzinga

-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Fee...

Capricor Therapeutics to Present at Upcoming Investor Conferences | Benzinga

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and ex...
Next 10